A Preliminary Study of JM-27: A Serum Marker That Can Specifically Identify Men With Symptomatic Benign Prostatic Hyperplasia
2007; Lippincott Williams & Wilkins; Volume: 177; Issue: 2 Linguagem: Inglês
10.1016/j.juro.2006.09.023
ISSN1527-3792
AutoresGrant W. Cannon, Chris Mullins, M. Scott Lucia, Simon W. Hayward, Victor K. Lin, Brian C.‐S. Liu, Kevin M. Slawin, Mark A. Rubin, Robert H. Getzenberg,
Tópico(s)Prostate Cancer Treatment and Research
ResumoNo AccessJournal of UrologyAdult urology1 Feb 2007A Preliminary Study of JM-27: A Serum Marker That Can Specifically Identify Men With Symptomatic Benign Prostatic Hyperplasia Grant W. Cannon, Chris Mullins, M. Scott Lucia, Simon W. Hayward, Victor Lin, Brian C.-S. Liu, Kevin Slawin, Mark A. Rubin, and Robert H. Getzenberg Grant W. CannonGrant W. Cannon James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland , Chris MullinsChris Mullins National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, Bethesda, Maryland , M. Scott LuciaM. Scott Lucia Prostate Diagnostic Laboratory and MTOPS Prostate Samples Analysis Consortium Pathology Coordinating Center, Department of Pathology, University of Colorado, Denver and Health Sciences Center, Aurora, Colorado , Simon W. HaywardSimon W. Hayward Departments of Urologic Surgery and Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee , Victor LinVictor Lin Department of Urology, The University of Texas Southwest Medical Center, Dallas, Texas , Brian C.-S. LiuBrian C.-S. Liu Molecular Urology Laboratory, Brigham and Women's Hospital, Boston, Massachusetts , Kevin SlawinKevin Slawin Scott Department of Urology, Baylor College of Medicine, Houston, Texas , Mark A. RubinMark A. Rubin Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts , and Robert H. GetzenbergRobert H. Getzenberg James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland View All Author Informationhttps://doi.org/10.1016/j.juro.2006.09.023AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Benign prostatic hyperplasia is a common disease in men that until recently was considered a single disease with varying symptoms. Our recent analysis has revealed that a molecular marker, JM-27, is able to distinguish at the tissue level between highly symptomatic individuals and those with histological disease. The goal of these studies was to determine if a serum based assay to detect JM-27 could distinguish men with different forms of benign prostatic hyperplasia. Materials and Methods: A serum based enzyme-linked immunosorbent assay was developed using a novel anti-JM-27 monoclonal antibody. The assay was sensitive, detecting JM-27 at the low ng/ml level within the serum. A quantitative measurement of serum JM-27 levels was performed in 68 patients. The patients consisted of 3 groups of 29 patients with asymptomatic benign prostatic hyperplasia (American Urological Association symptom score of 15 or less), 39 with symptomatic benign prostatic hyperplasia (American Urological Association symptom score 16 to 32) and 17 with confirmed prostate cancer. The assay cutoff was determined after a pilot run of samples and applied prospectively. Results: Using the determined cutoff, serum levels of JM-27 can distinguish between symptomatic and asymptomatic patient sets. The sensitivity and specificity of the assay are 90% and 77%, respectively. The presence of prostate cancer in these men does not appear to alter the marker levels. Conclusions: The present study is believed to represent the first characterization of a serum based marker for severe benign prostatic hyperplasia. References 1 : Benign prostatic hyperplasia: a review of its histogenesis and natural history. Prostate Suppl1996; 6: 67. Google Scholar 2 : alpha-Adrenoceptor antagonists in the treatment of benign prostate hyperplasia. Pharmacology2002; 65: 119. Google Scholar 3 : Economic costs of benign prostatic hyperplasia in the private sector. J Urol2005; 173: 1309. Link, Google Scholar 4 : Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival. Cancer Cell Int2005; 5: 8. Google Scholar 5 : alpha1-adrenergic receptors in the lower urinary tract and vascular bed: potential role for the alpha1d subtype in filling symptoms and effects of ageing on vascular expression. BJU Int2000; 85: 6. Google Scholar 6 : Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol2005; 40: 121. Google Scholar 7 : Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc Natl Acad Sci U S A2002; 99: 7598. Google Scholar 8 : Androgen regulation of JM-27 is associated with the diseased prostate. J Androl2004; 25: 618. Google Scholar 9 : Benign prostatic hyperplasia cell line viability and modulation of jm-27 by doxazosin and Ibuprofen. J Urol2005; 174: 375. Link, Google Scholar 10 : Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. Clin Chem2003; 49: 253. Google Scholar 11 : Correlation between the structure and function of the rabbit urinary bladder following partial outlet obstruction. J Urol2000; 163: 1349. Link, Google Scholar 12 : Effect of bladder outlet obstruction on the morphology, physiology, and pharmacology of the bladder. Prostate Suppl1990; 3: 9. Google Scholar © 2007 by American Urological AssociationFiguresReferencesRelatedDetailsCited byBechis S, Otsetov A, Ge R and Olumi A (2018) Personalized Medicine for the Management of Benign Prostatic HyperplasiaJournal of Urology, VOL. 192, NO. 1, (16-23), Online publication date: 1-Jul-2014.Mullins C, Lucia M, Hayward S, Lee J, Levitt J, Lin V, Liu B, Chinnaiyan A, Rubin M, Slawin K, Star R and Getzenberg R (2018) A Comprehensive Approach Toward Novel Serum Biomarkers for Benign Prostatic Hyperplasia: The MPSA ConsortiumJournal of Urology, VOL. 179, NO. 4, (1243-1256), Online publication date: 1-Apr-2008. Volume 177Issue 2February 2007Page: 610-614 Advertisement Copyright & Permissions© 2007 by American Urological AssociationKeywordsimmunoassayprostatic hyperplasiaurinary tractbiological markersMetricsAuthor Information Grant W. Cannon James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author Chris Mullins National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, Bethesda, Maryland More articles by this author M. Scott Lucia Prostate Diagnostic Laboratory and MTOPS Prostate Samples Analysis Consortium Pathology Coordinating Center, Department of Pathology, University of Colorado, Denver and Health Sciences Center, Aurora, Colorado More articles by this author Simon W. Hayward Departments of Urologic Surgery and Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee More articles by this author Victor Lin Department of Urology, The University of Texas Southwest Medical Center, Dallas, Texas More articles by this author Brian C.-S. Liu Molecular Urology Laboratory, Brigham and Women's Hospital, Boston, Massachusetts More articles by this author Kevin Slawin Scott Department of Urology, Baylor College of Medicine, Houston, Texas More articles by this author Mark A. Rubin Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts More articles by this author Robert H. Getzenberg James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author Expand All Advertisement PDF downloadLoading ...
Referência(s)